Voyager Therapeutics announces first patient dosed in RESTORE-1, phase 2 trial of VY-AADC
Voyager Therapeutics announced dosing of the first patient in RESTORE-1, a Phase 2, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of VY-AADC for treatment of Parkinson’s disease in patients with motor fluctuations that are refractory to medical management. December 10, 2018